NCT07208123

Brief Summary

This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). We will use single cell sequencing technology to analyze lung tissue samples from patients who underwent lung resection, with lung tissue from patients without COPD serving as controls. This research aims to provide insights into the pathogenesis of COPD.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
18mo left

Started Sep 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress31%
Sep 2025Dec 2027

First Submitted

Initial submission to the registry

September 27, 2025

Completed
3 days until next milestone

Study Start

First participant enrolled

September 30, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 6, 2025

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

October 6, 2025

Status Verified

September 1, 2025

Enrollment Period

1.3 years

First QC Date

September 27, 2025

Last Update Submit

September 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Transcriptomic profile analysis of lung tissues

    until end of surgery

Study Arms (1)

COPD group

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

150

You may qualify if:

  • Receiving lung resection surgery at the hospital for any reason;
  • Diagnosed with COPD according to the 2024 GOLD guidelines;
  • Tissue samples that meet collection requirements and are either agreed to be collected or already preserved;

You may not qualify if:

  • Improper preservation of pathological specimens, refusal to consent to sample collection, or incomplete clinical information;
  • Combined with other factors causing obstructive airflow limitation;
  • Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year;
  • Combined with Advanced lung cancer;
  • Receiving systemic immunosuppressive medications such as anti-rejection drugs;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200444, China

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

September 27, 2025

First Posted

October 6, 2025

Study Start

September 30, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Last Updated

October 6, 2025

Record last verified: 2025-09

Locations